Imugene granted HER-Vaxx immunotherapy patent in the US; shares rise 12%
The patent provides method of composition and method of use protection to 2036.
Company
Imugene Ltd
ASX:IMU
Imugene Ltd is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours. The company's unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Imugene is supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.
224 stories · page 9 of 12
Imugene appoints surgeon-scientist Dr Rebecca Auer to oncolytic virotherapy advisory board
Dr. Auer heads a research laboratory and is the principle investigator in related clinical trials.
Imugene’s immunotherapy strategy given stamp of approval in oversubscribed placement
The placement raised A$24.6 million and was well supported by existing investors and new sophisticated and institutional investors.
Imugene director increases stake, capital raising underway
Paul Hopper is an Australian biotech entrepreneur who has been associated with a number of biotechnology companies.
Imugene in trading halt with capital raising news pending
The company’s securities are in a trading halt until Monday, December 2, or when an announcement is made to the market.
Imugene plans two separate phase I clinical trials for CF33 oncolytic virus
CF33 is a highly potent, chimeric oncolytic poxvirus – a poxvirus refers to a large group of DNA viruses that cause smallpox and similar infectious diseases in vertebrates.
Imugene appoints distinguished physician and scientist to the Scientific Advisory Board
The company’s vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments – this vision is backed by a growing body of clinical evidence and peer-reviewed research.
Imugene shareholders vote yes to completing oncolytic virus acquisition, shares surge
“We are delighted to be able to complete the acquisition of Vaxinia Pty Ltd and City of Hope licence of such a promising next-generation oncolytic virus,” says MD and CEO Leslie Chong.
Imugene secures $4.13 million research and development tax refund
Imugene is planning two separate Phase 1 clinical trials in 2020 to test a CheckVacc construct and a Vaxinia construct of the CF33 oncolytic virus.
Imugene welcomes receipt of US Department of Defense grant for City of Hope cancer researchers
The grant focuses on the area of gastric cancer, a disease that disproportionately affects US military service members, veterans, and their beneficiaries.
Imugene plans to begin Phase 1 oncolytic virus technology clinical trials in 2020
Two separate Phase 1 clinical trials will be conducted in 2020 to test a CheckVacc construct and a Vaxinia construct of the oncolytic virus.
Imugene appoints world-renowned cancer researcher, physician and surgeon to head-up OV Scientific Advisory Board
A pioneer in the operating room and in the laboratory, Dr Fong, The Sangiacomo Family Chair in Surgical Oncology and chair of The City of Hope Dept of Surgery, is a recognised expert in liver and pancreatic cancer.
Imugene presents HER2 immuno-oncology vaccines success at ESMO ahead of 2020 studies
Inventor Ursula Wiedermann and investigators Tanios Bekaii-Saab and Joshua Tobias presented findings from early study of vaccines for gastric, colon and breast cancers.
Imugene to acquire exclusive licence for potentially transformational oncolytic virus technology
A phase-one clinical trial in 30 patients with advanced tumours is expected to start in 2020 across a number of US cancer centres.
Imugene reveals new clinical data for HER-Vaxx vaccine showing cancer-fighting response
HER-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours in gastric, breast, ovarian, lung and pancreatic cancers.
Imugene presents new HER-Vaxx cancer vaccine results
Results were presented at the ASCO annual meeting in Chicago, which attracts over 40,000 cancer specialists.
Imugene appoints venture capital executive to board
The company finished the March quarter with $21 million in the bank.
Imugene to present new data from HER-Vaxx cancer vaccine phase 1b trial
Imugene’s HER-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours that over-express the HER-2/neu receptor.
Imugene appoints global pharmaceutical executive to its board
Dr. Lesley Russell brings extensive pharmaceutical experience to the board including a number of cancer therapy collaborations with Teva Pharmaceuticals.
Imugene well-funded to progress clinical milestones
The company is currently fully funded in supporting all clinical research programs.